Advancements in Serological Biomarkers for Early Detection and Prognosis of Cancer

Saeid Azizi *

*Iranian Hospital, Dubai, UAE


Paper Received Date: 3rd November 2023
Paper Acceptance Date: 7th December 2023
Paper Publication Date: 14th December 2023

Abstract- Cancer remains a significant global health concern, and the development of effective strategies for early detection is of utmost importance. Serological biomarkers have emerged as promising tools in cancer research due to their non-invasive nature and potential for early detection. This review comprehensively examines recent advancements in serological biomarkers for the early detection and prognosis of cancer, with a specific focus on liquid biopsy, exosomal proteins, and circulating tumor DNA (ctDNA). Liquid biopsy, a minimally invasive technique, involves the analysis of biofluids such as blood for the presence of tumor-derived biomarkers, offering several advantages over traditional tissue biopsies, including real-time monitoring of tumor evolution and assessment of treatment response. The review critically evaluates the latest developments in liquid biopsy-based serological biomarkers and their implications for early cancer detection and prognostic evaluation, shedding light on their potential to revolutionize cancer diagnosis and management strategies.

Index Terms- Cancers, Cancer biomarkers, Early detection, Prognosis, Circulating tumor cells, Liquid Biopsy, Exosomal Proteins, Circulating Tumor DNA (ctDNA).

I. INTRODUCTION

Cancer continues to be a leading cause of mortality worldwide, posing significant challenges to public health systems. The success of cancer management heavily relies on early detection, accurate prognosis, and timely intervention. Over the years, significant strides have been made in understanding the molecular underpinnings of cancer, leading to the development of innovative diagnostic and prognostic tools. Among these advancements, serological biomarkers have emerged as promising non-invasive and easily accessible indicators of cancer presence and progression.

This review paper aims to provide a comprehensive overview of the recent advancements in serological biomarkers for the early detection and prognosis of cancer. Specifically, we focus on three key areas of investigation: liquid biopsy, exosomal proteins, and circulating tumor DNA (ctDNA). Although these techniques are still under research and experimental testing, our aim is to consolidate the current knowledge surrounding these biomarkers and shed light on their potential applications in clinical practice.

Subsequently, early detection of cancer is pivotal for successful treatment and improved patient survival rates. Serological biomarkers offer a non-invasive and accessible method for identifying cancer at its earliest stages. These biomarkers can include specific proteins, enzymes, genetic material (such as circulating tumor DNA), or autoantibodies produced in response to cancer-related antigens. By employing serological biomarkers in screening programs and risk assessment strategies, healthcare professionals can identify individuals at high risk of developing cancer or monitor high-risk populations effectively. Biomarkers such as prostate-specific antigen (PSA) for prostate cancer or carcinoembryonic antigen (CEA) for colorectal cancer play a crucial role in population-based screening programs, facilitating early intervention and subsequent improved outcomes.

Additionally, accurate prognosis is critical for determining appropriate treatment strategies and estimating patient outcomes. Serological biomarkers provide valuable prognostic information that aids in treatment selection, patient counseling, and follow-up strategies. Changes in the levels of serological biomarkers during and after treatment can reflect the tumor burden and response to therapy. Biomarkers like prostate-specific antigen (PSA) or cancer antigen 15-3 (CA 15-3) can help monitor the efficacy of treatment and guide subsequent therapeutic interventions. Additionally, serological biomarkers have the potential to predict disease recurrence and metastasis. Biomarkers such as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), or specific protein markers can serve as indicators of residual disease or metastatic potential, enabling clinicians to intervene early and improve patient outcomes.

This publication is licensed under Creative Commons Attribution CC BY.
While the potential of serological biomarkers for early detection and prognosis of cancer is promising, several challenges exist. The specificity and sensitivity of serological biomarkers are of utmost importance to accurately differentiate between cancer and benign conditions. False positives and false negatives can lead to unnecessary procedures or missed diagnoses, respectively. Additionally, the identification and validation of novel biomarkers, as well as the standardization of testing methods, are ongoing challenges in the field. Overcoming these challenges will require collaborative efforts among researchers, clinicians, and regulatory authorities to ensure the effective implementation of serological biomarkers in routine clinical practice.

While the aforementioned serological biomarkers hold immense potential in cancer research, it is essential to critically evaluate their strengths, limitations, and practical considerations. Furthermore, we discuss emerging technologies, ongoing research efforts, and potential future directions in the field. By providing a comprehensive synthesis of the current knowledge and advancements, this review aims to contribute to the understanding and utilization of serological biomarkers for early cancer detection and improved prognostication.

II. OVERVIEW OF CANCER BIOMARKERS

Cancer biomarkers play a crucial role in various aspects of cancer research and clinical practice. These biomarkers are measurable indicators found in blood, tissues, or other bodily fluids that can provide valuable information about the presence, behavior, and treatment response of cancer. They are extensively studied to improve early detection, prognosis prediction, treatment selection, and monitoring of cancer patients.

The field of cancer biomarkers is diverse, encompassing various types of molecules, including proteins, nucleic acids (DNA, RNA), metabolites, and circulating tumor cells. These biomarkers can be obtained through minimally invasive methods such as blood tests, urine samples, or tissue biopsies. By analyzing the levels or alterations of specific biomarkers, clinicians and researchers can gain insights into the underlying biology of cancer and develop more effective diagnostic and therapeutic strategies.

One of the primary applications of cancer biomarkers is in early detection. Early detection is crucial for improving patient outcomes as it allows for timely intervention and treatment initiation. Biomarkers can aid in the identification of pre-cancerous lesions or the detection of cancer at an early stage when it is more amenable to treatment. Examples of well-known cancer biomarkers used for early detection include prostate-specific antigen (PSA) for prostate cancer and carcinoembryonic antigen (CEA) for colorectal cancer.

Cancer biomarkers also play a significant role in prognostic assessment. They can provide information about the aggressiveness of the disease, the likelihood of recurrence, and overall patient survival. Prognostic biomarkers assist clinicians in tailoring treatment strategies, determining the need for adjuvant therapies, and identifying patients who may benefit from more aggressive interventions. For example, the expression of estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) in breast cancer is used to predict patient outcomes and guide treatment decisions.

In addition to diagnosis and prognosis, cancer biomarkers are essential in guiding treatment decisions. They can help predict the response to specific therapies and identify patients who are more likely to benefit from targeted treatments. For instance, the presence of certain genetic mutations, such as epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer, can guide the selection of targeted therapies like tyrosine kinase inhibitors.

Moreover, biomarkers are valuable tools for monitoring treatment response and detecting disease recurrence. By regularly measuring biomarker levels during and after treatment, clinicians can assess the effectiveness of therapy and make timely adjustments if necessary. Rising levels of certain biomarkers may indicate treatment resistance or disease progression, prompting the need for alternative therapeutic approaches.

While cancer biomarkers hold tremendous potential, their development and validation require rigorous scientific investigation. Researchers must conduct large-scale studies to establish their clinical utility, validate their specificity and sensitivity, and determine appropriate cutoff values. Standardized assays and protocols are crucial to ensure the reproducibility and reliability of biomarker measurements across different laboratories and clinical settings.

III. LIQUID BIOPSY AS A CANCER BIOMARKER

A. Definition and Principles of Liquid Biopsy:

Liquid biopsy is a non-invasive diagnostic method that involves the analysis of various biomarkers present in biofluids such as blood, urine, and cerebrospinal fluid. Unlike traditional tissue biopsies that require invasive procedures, liquid biopsy provides a minimally invasive alternative for assessing the genetic and molecular characteristics of tumors. The key principle behind liquid biopsy is the
detection and analysis of tumor-derived components, such as circulating tumor cells (CTCs), cell-free DNA (cfDNA), and extracellular vesicles (EVs), which carry valuable information about cancer progression and response to treatment.

B. Advancements in Liquid Biopsy-Based Biomarkers:

- **Detection and Analysis of Circulating Tumor Cells (CTCs):**
  CTCs are cancer cells that detach from the primary tumor and enter the bloodstream. Recent advancements in technology have enabled the isolation and characterization of CTCs from blood samples. These cells can provide valuable insights into tumor heterogeneity, metastasis, and treatment resistance. By analyzing CTCs, researchers can identify specific mutations, gene expression patterns, and other biomarkers that aid in understanding the tumor's characteristics and guiding treatment decisions.

- **Analysis of Cell-Free DNA (cfDNA):**
  cfDNA refers to the fragmented DNA released by cells into the bloodstream. Tumors shed cfDNA containing tumor-specific genetic alterations, such as mutations, copy number variations, and epigenetic modifications. Through techniques like next-generation sequencing, cfDNA can be analyzed to detect and monitor genetic alterations associated with cancer. This approach is particularly useful for monitoring treatment response, detecting minimal residual disease, and identifying emerging drug resistance mutations.

- **Extracellular Vesicles as Carriers of Biomarkers:**
  Extracellular vesicles, including exosomes and microvesicles, are small membranous structures released by cells into biofluids. These vesicles carry various biomolecules, including proteins, nucleic acids, and lipids. Researchers have discovered that tumor-derived EVs contain tumor-specific molecules, such as DNA, RNA, and proteins. By isolating and analyzing EVs, liquid biopsy can provide valuable information about the tumor's genetic makeup, signaling pathways, and microenvironment, contributing to a better understanding of cancer biology.

C. Clinical Implications and Applications of Liquid Biopsy-Based Biomarkers:

- **Diagnosis and Early Detection of Cancer:**
  Liquid biopsy holds great promise for early cancer detection and diagnosis. By detecting tumor-derived biomarkers in blood samples, it can identify the presence of cancer before it becomes clinically apparent or detectable by imaging methods. Liquid biopsy-based tests have shown encouraging results in detecting various cancers, including lung, breast, colorectal, and prostate cancers. Early detection enables timely intervention, leading to improved treatment outcomes and patient survival rates.

- **Monitoring Treatment Response and Disease Progression:**
  Liquid biopsy offers a dynamic and non-invasive approach to monitor treatment response and disease progression. By tracking genetic alterations and biomarker levels over time, liquid biopsy can help assess the effectiveness of treatment, detect treatment resistance, and guide therapeutic adjustments. It allows clinicians to make informed decisions regarding treatment strategies, including the selection of targeted therapies, immunotherapies, or personalized treatment regimens.

- **Detection of Minimal Residual Disease:**
  Minimal residual disease (MRD) refers to the small number of cancer cells that remain after treatment, potentially leading to disease recurrence. Liquid biopsy-based techniques can detect and monitor MRD by analyzing CTCs or residual tumor DNA in post-treatment blood samples. Early identification of MRD can prompt the initiation of additional treatments or intensification of existing therapies to prevent disease relapse.

IV. EXOSOMAL PROTEINS AS A CANCER BIOMARKER

A. Role of Exosomes in Cancer and Their Potential as Biomarkers:

Exosomes are small extracellular vesicles released by various cell types, including cancer cells, into the extracellular space. They play a crucial role in intercellular communication by transporting bioactive molecules, including proteins, nucleic acids, and lipids, between cells. In the context of cancer, exosomes have been shown to contribute to tumor growth, metastasis, and immune evasion. Due to their ability to reflect the characteristics of parent cells, exosomes have emerged as a valuable source of biomarkers for cancer diagnosis, prognosis, and treatment monitoring.

B. Recent Discoveries of Exosomal Proteins in Cancer:
Identification and Characterization of Specific Exosomal Proteins:

Recent research efforts have focused on identifying and characterizing specific proteins carried by exosomes derived from cancer cells. Techniques such as mass spectrometry and proteomic profiling have facilitated the discovery of numerous exosomal proteins associated with cancer. These proteins can include surface receptors, signaling molecules, enzymes, transcription factors, and cytoskeletal proteins, among others.

Diagnostic and Prognostic Applications of Exosomal Proteins:

Exosomal proteins hold significant potential as diagnostic and prognostic biomarkers for cancer. By analyzing the protein composition of exosomes isolated from patient biofluids, researchers can identify specific protein signatures that distinguish cancer patients from healthy individuals. Additionally, certain exosomal protein markers have shown promise in predicting disease progression, metastasis, and overall patient survival.

C. Clinical Implications and Potential Applications of Exosomal Protein Biomarkers:

Detection and Monitoring of Cancer:

Exosomal proteins can be utilized for the detection and monitoring of various types of cancer. The analysis of exosomal protein markers in biofluids, such as blood or urine, provides a non-invasive approach to assess the presence and progression of cancer. Changes in the abundance or expression patterns of specific exosomal proteins can indicate the presence of a tumor, potentially enabling early cancer detection and intervention.

Predictive Biomarkers for Treatment Response and Personalized Therapy:

Exosomal proteins have the potential to serve as predictive biomarkers for treatment response and facilitate personalized therapy decisions. By monitoring changes in exosomal protein levels during treatment, clinicians can assess treatment efficacy and predict patient response. Additionally, specific exosomal protein markers may indicate the likelihood of treatment resistance or sensitivity to certain therapies, allowing for the tailoring of treatment strategies to individual patients.

The clinical implications and applications of exosomal protein biomarkers include improving the accuracy of cancer diagnosis, enabling early intervention, and guiding treatment decisions. By harnessing the information carried by exosomal proteins, researchers and clinicians can gain insights into the underlying biology of tumors and develop more effective and personalized treatment approaches.

However, further research is needed to overcome challenges associated with standardization, sensitivity, and specificity in the analysis of exosomal proteins. Advancements in technology and methodologies will be essential for the translation of exosomal protein biomarkers into clinical practice, ultimately leading to improved cancer management and patient outcomes.

V. CIRCULATING TUMOR DNA (ctDNA) AS A CANCER BIOMARKER

A. Definition and characteristics of ctDNA

Circulating Tumor DNA (ctDNA) refers to small fragments of DNA released into the bloodstream by tumor cells. Tumors shed these DNA fragments as they grow and undergo various biological processes, such as apoptosis, necrosis, and active secretion. ctDNA carries genetic information specific to the tumor, making it a valuable biomarker for cancer detection, monitoring, and treatment evaluation.

ctDNA exhibits several characteristics that make it an attractive target for cancer research:

Tumor-specific mutations: ctDNA carries genetic alterations that are specific to the tumor cells from which it originates. These mutations can include single nucleotide variants, insertions, deletions, rearrangements, and copy number variations. By analyzing these mutations, researchers can gain insights into the genomic landscape of the tumor and its heterogeneity.
Low abundance: ctDNA exists in low quantities within the bloodstream compared to normal cell-free DNA. Its detection and analysis require sensitive techniques capable of identifying and quantifying rare ctDNA fragments among a large background of normal DNA. Overcoming the challenge of low ctDNA abundance has been a focus of technological advancements in ctDNA analysis.

Dynamic nature: ctDNA levels can fluctuate over time due to changes in tumor burden, treatment response, and disease progression. Monitoring these changes provides insights into the tumor’s behavior and response to therapies. Additionally, ctDNA can reflect the emergence of treatment-resistant clones or the presence of minimal residual disease.

B. Recent advancements in ctDNA analysis and detection

- Next-generation sequencing (NGS) and digital PCR techniques:
  NGS allows for high-throughput sequencing of multiple DNA fragments simultaneously. This technology enables the identification of genetic alterations in ctDNA, such as point mutations, gene fusions, and structural variations. NGS-based approaches, such as targeted sequencing panels and whole-exome sequencing, have been developed to detect these alterations with high accuracy. Digital PCR is a highly sensitive method that allows for absolute quantification of ctDNA in a sample, even at low concentrations, by partitioning the DNA into thousands of individual reactions.

- Identification of specific mutations and alterations in ctDNA:
  Advances in ctDNA analysis have facilitated the detection of specific tumor-associated mutations and alterations. These may include driver mutations or alterations in genes related to cancer development and progression. Through targeted sequencing or customized assays, researchers can now detect these alterations with high sensitivity and specificity. Additionally, the development of multiplexed assays allows the simultaneous detection of multiple mutations or alterations in a single test, enhancing the efficiency of ctDNA analysis.

C. Clinical applications and significance of ctDNA as a biomarker

- Early cancer detection and screening:
  ctDNA analysis holds promise as a non-invasive tool for early cancer detection and screening. By detecting cancer-specific mutations in blood samples, ctDNA analysis may help identify tumors at an earlier stage when treatment options are more effective. Additionally, ctDNA-based liquid biopsies may complement or replace traditional tissue biopsies, which can be invasive and challenging to obtain in certain cases. Early studies have shown promising results in detecting ctDNA in various cancer types, including lung, colorectal, breast, and pancreatic cancer.

- Tracking treatment response and minimal residual disease:
  Monitoring ctDNA levels during cancer treatment provides real-time information about treatment response and disease progression. Changes in ctDNA levels can indicate treatment efficacy or resistance, enabling physicians to adjust therapeutic strategies promptly. ctDNA analysis is particularly useful in detecting minimal residual disease (MRD), which refers to the presence of small amounts of cancer cells after treatment. Detecting MRD can help identify patients at high risk of recurrence and guide decisions regarding adjuvant therapies or closer surveillance.

VI. CONCLUSION

In conclusion, the review highlights the significant progress made in the field of serological biomarkers, specifically focusing on liquid biopsy, exosomal proteins, and circulating tumor DNA (ctDNA) as promising tools for the early detection and prognosis of cancer. The introduction of liquid biopsy as a non-invasive method for obtaining tumor-derived materials from body fluids has revolutionized cancer diagnostics, allowing for the analysis of ctDNA and exosomal proteins as valuable biomarkers. These advancements offer tremendous potential in enhancing early cancer detection and monitoring disease progression, ultimately leading to improved patient outcomes and personalized treatment strategies.

VII. REFERENCES


[7] Vandekerkhove G;Struss WJ;Annala M;Kallio HML;Khalaf D;Warner EW;Herberts C;Ritch E;Beja K;Loktionova Y;Hurtado-Coll A;Fazli L;So A;Black PC;Nyktar M;Tammela T;Chi KN;Gleave ME;Wyatt AW; (n.d.). Circulating tumor DNA abundance and potential utility in de novo metastatic prostate cancer. European urology. https://pubmed.ncbi.nlm.nih.gov/30638634/


[14] Zhu L.;Sun HT;Wang S;Huang SL;Zheng Y;Wang CQ;Hu BY;Qin W;Zou TT;Fu Y;Shen XT;Zhu WW;Geng Y;Lu L;Jia HL;Qin LX;Dong QZ; (n.d.). Isolation and characterization of exosomes for cancer research. Journal of hematology &amp; oncology. https://pubmed.ncbi.nlm.nih.gov/33168028/


AUTHORS
First Author – Saeid Azizi, Specialist histopathologist and clinical pathologist, Chief laboratory department, Iranian hospital, Dubai, UAE

Correspondence Author – Saeid Azizi, saeed_azizi2003@yahoo.com, 00971509385022